neutralizing antibody living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 hospitalized
	COVID 19 hospitalized	COVID-19 mild to moderate	COVID-19 severe or critically
neutralizing antibody	ITAC
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)	ACTIV-3 ...
bamlanivimab monotherapy	ACTIV-3/TICO LY-CoV555
casirivimab/imdevimab (Ronapreve)	RECOVERY ...	Somersan-Karakaya ...
cilgavimab and tixagevimab (Evusheld)	ACTIV-3/TICO ...
equine polyclonal antibodies INM005			Lopardo
sotrovimab (Xevudy; VIR-7831)	ACTIV-3/ TICO ...

5570	CT-P59 1.2, 2020	2	1	0	excluded		risk of bias not avaialble
6137	CT-P59 3.2 part 1, 2021	1	1	0			risk of bias not avaialble
6456	ACTIV-2 (BRII-196 and BRII-198), 0	1	1	0			risk of bias not avaialble
6528	BLAZE-4, 0	1	1	0			risk of bias not avaialble
6672	TACKLE, 0	1	1	0			risk of bias not avaialble
6708	Webb, 2021	0	13	0	selection pending
6920	Rainwater-Lovett, 2021	0	13	0	selection pending
6921	Bariola, 2021	1	13	0		not a RCT	risk of bias not avaialble
7021	BLAZE 4 LY-CoV1404, 0	1	1	0			risk of bias not avaialble
8968	OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021	1	1	3			high risk of bias
9265	OPTIMISE-C19 (bamlanivimab monotherapy vs casirivimab-imdevimab), 2021	0	1	0	selection pending
9266	CT-P59 3.2 part 2, 2021	1	1	0			risk of bias not avaialble
9481	Kim, 2022	0	0	0	selection pending
9866	Jurdi, 2022	1	11	0		not a RCT	risk of bias not avaialble
10191	Chen, 2022	0	10	0	selection pending